Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
group b streptococcus capsular polysaccharide III-CRM197 conjugate
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a monovalent conjugate vaccine component consisting of the capsular polysaccharide of Group B Streptococcus (GBS) serotype III covalently linked to the CRM197 carrier protein (a non-toxic recombinant variant of diphtheria toxin). Developed by Pfizer, it is designed to elicit a protective immune response against *Streptococcus agalactiae* serotype III infections, which are a leading cause of neonatal sepsis and meningitis. The conjugation to CRM197 converts the T-cell independent polysaccharide antigen into a T-cell dependent antigen, enhancing immunogenicity and inducing immunological memory, particularly in infants and through maternal immunization. It is currently a constituent of Pfizer's hexavalent GBS vaccine candidate (GBS6).
- Other names
- GBS Type III-CRM197 conjugateGBS III-CRM197Group B Streptococcus serotype III conjugate
02
Targets
GBS CPS III (Group B Streptococcus capsular polysaccharide type III)
Beyond the preview
Go deeper on group b streptococcus capsular polysaccharide III-CRM197 conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on group b streptococcus capsular polysaccharide III-CRM197 conjugate.